Events and conditions that could cast significant doubt on the going-concern assumption
Carna Biosciences,Inc. (filing company)
BTK inhibitor docirbrutinib (AS-1763), CDC7 inhibitor monzosertib (AS-0141)
Recognition of losses associated with substantial upfront investment in research and development, primarily clinical trial-related expenses. Funds on hand as of 30 September 2026 may be insufficient to cover the research and development required from the consolidated accounting period of the following quarter onward.
Operating loss of ¥1,532 million, ordinary loss of ¥1,591 million, quarterly net loss attributable to owners of the parent of ¥1,633 million, and negative net assets of ¥886 million (accounting classifications: operating loss, ordinary loss, quarterly net loss, net assets)
Nine-month cumulative consolidated period of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026), and as of 30 September 2026
There is no change to the consolidated earnings forecast for the fiscal year ending December 2026.
Company response
(1) Advance clinical trials for pipeline candidates in development and obtain upfront licensing fees and milestone revenue by entering into license agreements; (2) expand revenue in the drug discovery support business; and (3) implement measures to strengthen the financial foundation, including financing
The company will advance clinical trials, seek upfront fees and other revenue from out-licensing its development pipeline, expand revenue in the drug discovery support business, and work to strengthen its financial foundation, including through financing. If funds become insufficient, the company will consider raising additional funds as necessary.
| Item | Details |
|---|---|
| Event name | Events and conditions that could cast significant doubt on the going-concern assumption |
| Date of occurrence | 30 September 2026 |
| Subject Entity | Carna Biosciences,Inc. (filing company) |
| Target Locations / Products | BTK inhibitor docirbrutinib (AS-1763), CDC7 inhibitor monzosertib (AS-0141) |
| Cause | Recognition of losses associated with substantial upfront investment in research and development, primarily clinical trial-related expenses. Funds on hand as of 30 September 2026 may be insufficient to cover the research and development required from the consolidated accounting period of the following quarter onward. |
| Amount of Impact on Business Performance | Operating loss of ¥1,532 million, ordinary loss of ¥1,591 million, quarterly net loss attributable to owners of the parent of ¥1,633 million, and negative net assets of ¥886 million (accounting classifications: operating loss, ordinary loss, quarterly net loss, net assets) |
| Accounting period in which recognized | Nine-month cumulative consolidated period of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026), and as of 30 September 2026 |
| Impact on Earnings Forecast | There is no change to the consolidated earnings forecast for the fiscal year ending December 2026. |
| Measures to prevent recurrence | (1) Advance clinical trials for pipeline candidates in development and obtain upfront licensing fees and milestone revenue by entering into license agreements; (2) expand revenue in the drug discovery support business; and (3) implement measures to strengthen the financial foundation, including financing |
| Outlook | The company will advance clinical trials, seek upfront fees and other revenue from out-licensing its development pipeline, expand revenue in the drug discovery support business, and work to strengthen its financial foundation, including through financing. If funds become insufficient, the company will consider raising additional funds as necessary. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company has recognized losses due to substantial upfront investment in research and development, primarily clinical trial-related expenses, and funds on hand at the end of the period may be insufficient to cover the research and development required from the following quarter onward.